15 December 2021 - Another new cancer medicine from AstraZeneca.

The TGA has approved the orphan drug selumetinib sulphate (Koselugo) for the treatment of paediatric patients aged 2 years and above, with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas.

Read TGA prescription medicine decision summary for selumetinib sulphate